INCORPORATION OF SEQUENCE LISTING

A' cont.

A paper copy of the Sequence Listing and a computer readable form of the sequence listing on diskette, containing the file named SeqList.txt, which is 6581 bytes in size (measured in MS-DOS), and which was created on April 17, 2001, and recorded on April 28, 2001, are herein incorporated by reference.

Please **delete** the paragraph beginning with the phrase "Fig. 5:" on page 6 **and replace** it with the following paragraph:

A2

Fig 5: cDNA (upper) (SEQ ID NO: 1) and deduced amino acid sequence (lower) (SEQ ID NO:2) of ACT-4-h-1. The Figure indicates the locations of an N-terminal signal sequence, two possible signal cleavage sites (vertical arrows), two glycosylation sites (gly), a transmembrane domain (TM), a stop codon and a poly-A signal sequence.

Please **delete** the paragraph beginning with the phrase "All hybridomas" on page 30 **and replace** it with the following paragraph:

A3

All hybridomas, triomas and other cell lines producing the antibodies and their fragments discussed, *supra*, are expressly included in the invention. These include the hybridoma line HBL106, deposited as ATCC Accession No. ATCC HB 11483, which produces the L106 mouse antibody.

Please **delete** the paragraph beginning with the phrase "Mice were immunized" and which spans from page 42, line 30 to page 43, line 2 and **replace it** with the following paragraph:

A4

Mice were immunized with PHA-transformed T-lymphoblasts. Splenocytes from immunized mice were fused with SP2/O myeloma cells and hybridomas secreting antibodies specific for the T-cell clone were selected. The hybridomas were cloned by limiting dilution. A monoclonal antibody, designated L106, produced by one of the resulting hybridoma, was selected for further characterization. The L106 antibody was found to have an IgG1 isotype. A hybridoma producing the antibody, designated HBL106 has been deposited at the American